Proactive Investors
13 Jul 2026, 11:36 UTC · 1h ago
UBS stays positive on AstraZeneca ahead of second-quarter results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
13 Jul 2026, 11:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
UBS maintains a 'buy' rating on AstraZeneca with a 12-month price target of 17,600p, significantly above the current market price. — A high-conviction price target from a major investment bank typically provides bullish support for the stock price.
+0.60UBS flags higher risk for lung and breast cancer trial readouts expected in the second half of the year. — Increased risk in near-term clinical catalysts creates potential for negative price volatility if results miss expectations.
-0.40UBS views AstraZeneca's $80 billion annual revenue target by 2030 as achievable due to expected blockbuster readouts in 2027. — Long-term revenue validation supports the company's growth thesis and valuation floor.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
UBS expects AstraZeneca to report solid Q2 results on July 27, though it sees little room for the company to raise full-year guidance. — While solid results are positive, the lack of guidance upgrades suggests limited upside momentum from the immediate earnings call.
+0.20Which stocks this story touches
The company reported strong first-half performance with growth in recurring revenue and improving profitability.
UBS reiterated a 'buy' rating and expects solid second-quarter results and growth in revenue and earnings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
